Zacks Investment Research Upgrades Ekso Bionics (EKSO) to Hold

Ekso Bionics (NASDAQ:EKSO) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Wednesday.

According to Zacks, “Ekso Bionics Holdings, Inc. is engaged in designing, developing and selling wearable robots or exoskeletons for the medical, military, industrial and consumer markets. The company’s operating segment consists of Engineering Services and Medical segments. It operates primarily in North America, Western Europe, the Middle East and South Africa. Ekso Bionics Holdings, Inc. is headquartered in Richmond, California. “

Separately, ValuEngine upgraded shares of Ekso Bionics from a “hold” rating to a “buy” rating in a research note on Thursday, July 12th.

NASDAQ EKSO opened at $2.05 on Wednesday. Ekso Bionics has a 52-week low of $1.02 and a 52-week high of $4.77. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.17 and a quick ratio of 1.92. The stock has a market cap of $114.36 million, a P/E ratio of -2.30 and a beta of -0.34.

Ekso Bionics (NASDAQ:EKSO) last posted its quarterly earnings data on Tuesday, August 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). Ekso Bionics had a negative return on equity of 169.75% and a negative net margin of 327.12%. The company had revenue of $2.97 million for the quarter, compared to analysts’ expectations of $3.03 million. On average, equities research analysts anticipate that Ekso Bionics will post -0.45 EPS for the current year.

A hedge fund recently bought a new stake in Ekso Bionics stock. Bristol Advisors LLC bought a new position in Ekso Bionics Holdings Inc (NASDAQ:EKSO) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 45,532 shares of the company’s stock, valued at approximately $107,000. Bristol Advisors LLC owned approximately 0.07% of Ekso Bionics as of its most recent SEC filing. Institutional investors own 38.43% of the company’s stock.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.

Featured Story: Earnings Reports

Get a free copy of the Zacks research report on Ekso Bionics (EKSO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply